KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Medpace Holdings (MEDP) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Medpace Holdings (MEDP) over the last 11 years, with Q3 2025 value amounting to $31.7 million.

  • Medpace Holdings' Tax Provisions rose 4183.89% to $31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $86.4 million, marking a year-over-year increase of 2882.63%. This contributed to the annual value of $71.5 million for FY2024, which is 3530.03% up from last year.
  • As of Q3 2025, Medpace Holdings' Tax Provisions stood at $31.7 million, which was up 4183.89% from $34.3 million recorded in Q2 2025.
  • Medpace Holdings' Tax Provisions' 5-year high stood at $34.3 million during Q2 2025, with a 5-year trough of $2.8 million in Q2 2021.
  • Its 5-year average for Tax Provisions is $13.2 million, with a median of $12.6 million in 2022.
  • In the last 5 years, Medpace Holdings' Tax Provisions soared by 35926.6% in 2022 and then crashed by 6492.0% in 2025.
  • Medpace Holdings' Tax Provisions (Quarter) stood at $5.9 million in 2021, then dropped by 15.49% to $5.0 million in 2022, then surged by 149.43% to $12.4 million in 2023, then surged by 35.9% to $16.9 million in 2024, then skyrocketed by 87.98% to $31.7 million in 2025.
  • Its last three reported values are $31.7 million in Q3 2025, $34.3 million for Q2 2025, and $3.6 million during Q1 2025.